Stockscreener 앱 받기
1.0299
6.82%
-0.0701
전일 마감가:
$1.10
열려 있는:
$1.08
하루 거래량:
338.33K
Relative Volume:
0.33
시가총액:
$95.72M
수익:
$34.48M
순이익/손실:
$-102.07M
주가수익비율:
-0.7054
EPS:
-1.46
순현금흐름:
$-104.90M
1주 성능:
+25.17%
1개월 성능:
+28.88%
6개월 성능:
-48.23%
1년 성능:
-66.83%
1일 변동 폭
$1.015
$1.08
1주일 범위
$0.7691
$1.12
52주 변동 폭
$0.66
$3.19
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
CRBU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.0291 | 72.80M | 34.48M | -102.07M | -104.90M | -1.46 |
|
ONC
Beigene Ltd Adr
|
237.28 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.24 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.39 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.01 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.22 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - MSN
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33 - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for CRBU - Defense World
Dimensional Fund Advisors LP Sells 321,867 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Barclays PLC Grows Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Caribou Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - ACCESS Newswire
Caribou Biosciences (CRBU) Receives a Buy from Bank of America Securities - The Globe and Mail
Shareholders that Lost Money on Caribou Biosciences, Inc. (CRBU) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
RBC Lowers Price Target on Caribou Biosciences to $10 From $11, Keeps Outperform, Speculative Risk - marketscreener.com
Envestnet Asset Management Inc. Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Comparing Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) - Defense World
Ratio Revelations: Caribou Biosciences Inc (CRBU)’s Financial Metrics in the Spotlight - DWinneX
Leading CRISPR Company Caribou Biosciences to Reveal Latest Pipeline Updates at Major Healthcare Conference - Stock Titan
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference - The Manila Times
Caribou Biosciences (CRBU) to Release Quarterly Earnings on Tuesday - Defense World
Levi & Korsinsky Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Investors Can Still File Late Claims for Caribou Biosciences $3.9M Settlement Payouts - TradingView
HC Wainwright Issues Optimistic Forecast for CRBU Earnings - Defense World
Caribou Biosciences Inc [CRBU] Records 200-Day SMA of $1.6979 - knoxdaily.com
Taking the lead: Caribou Biosciences Inc (CRBU) - Sete News
Caribou Biosciences Investors Drop Suit Over Cell Therapy, Cash - Bloomberg Law News
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou B - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Is Caribou Biosciences Inc (CRBU) worth investing in despite its undervalued state? - uspostnews.com
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know - Yahoo
Caribou Biosciences Inc (NASDAQ: CRBU) -0.30% Decline Turns Investors Away - Stocksregister
Geode Capital Management LLC Sells 58,048 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
H.C. Wainwright cuts Caribou Biosciences stock target to $3 By Investing.com - Investing.com India
H.C. Wainwright cuts Caribou Biosciences stock target to $3 - Investing.com Australia
Caribou Biosciences (CRBU) Target Price Cut Amid Strategic Shift - GuruFocus
Quarterly Snapshot: Quick and Current Ratios for Caribou Biosciences Inc (CRBU) - DWinneX
Caribou Biosciences Inc (CRBU) Stock: A Year of Decreases and Increases - investchronicle.com
Caribou Biosciences Inc (CRBU) receives an In-line rating from Evercore ISI - knoxdaily.com
Caribou Biosciences (CRBU) Target Price Cut Amid Strategic Shift | CRBU Stock News - GuruFocus
Caribou Biosciences (CRBU) Sees Price Target Cut Amid Strategic - GuruFocus
Russell Investments Group Ltd. Boosts Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Lost Money on Caribou Biosciences, Inc. (CRBU)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies - MedCity News
Caribou Biosciences (CRBU) Restructures, Focuses on Key Oncology Programs - GuruFocus
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
2.08%
자본화:
|
볼륨(24시간):